for link http://www.bmj.com/content/356/bmj.j3961, I get page not found.
New Guidelines Issued on HIV Treatment During Pregnancy — Physician’s First Watch
New Guidelines Issued on HIV Treatment During Pregnancy
By Kelly Young
Tenofovir-emtricitabine should not be a first treatment choice for women with HIV who are pregnant, according to new patient-centered guidelines from The BMJ Rapid Recommendations panel. This contrasts with many current HIV treatment guidelines.
In a weak recommendation, the group says a regimen that includes zidovudine and lamivudine is preferred over one including tenofovir or emtricitabine because the latter "probably" increase risk for early infant death and preterm delivery.
In a strong recommendation, they advise using alternatives to regimens containing tenofovir, emtricitabine, and lopinavir/ritonavir. Adding lopinavir/ritonavir is associated with even greater neonatal risks.
Certain women might opt for tenofovir and emtricitabine, including those who are coinfected with hepatitis B and have a high risk for passing the virus to the infant, or those who have severe anemia, drug allergy or intolerance, or infections resistant to zidovudine or lamivudine.